Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XLRN
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.71015 billion
  • Outstanding Shares: 38,685,000
Average Prices:
  • 50 Day Moving Avg: $37.79
  • 200 Day Moving Avg: $32.25
  • 52 Week Range: $23.07 - $41.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13.14 million
  • Price / Sales: 111.90
  • Book Value: $4.88 per share
  • Price / Book: 7.79
  • EBITDA: ($96,080,000.00)
  • Net Margins: -724.22%
  • Return on Equity: -44.67%
  • Return on Assets: -40.14%
  • Current Ratio: 10.39%
  • Quick Ratio: 10.39%
  • Average Volume: 429,459 shs.
  • Beta: 1.66
  • Short Ratio: 16.06

Frequently Asked Questions for Acceleron Pharma (NASDAQ:XLRN)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.12. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $3.69 million. Acceleron Pharma had a negative return on equity of 44.67% and a negative net margin of 724.22%. The firm's revenue for the quarter was down 3.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.59) earnings per share. View Acceleron Pharma's Earnings History.

When will Acceleron Pharma make its next earnings announcement?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Acceleron Pharma.

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?

17 analysts have issued twelve-month price targets for Acceleron Pharma's stock. Their predictions range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's stock price to reach $43.67 in the next year. View Analyst Ratings for Acceleron Pharma.

What are analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • 1. Cann analysts commented, "Acceleron Pharma announced today that The Lancet Oncology has published results from the phase II study of Luspatercept in patients with lower-risk myelodysplastic syndromes (MDS). Acceleron reported that the article, entitled Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2 dose-finding study with long-term extension study" is now available online and will be published in a future print issue of The Lancet Oncology. The journal also published online a companion Comment article, Defeating anaemia in myelodysplastic syndromes: another step forward," by Valeria Santini, M.D., Associate Professor of Hematology at the University of Florence Medical School in Florence, Italy." (9/5/2017)
  • 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
  • 3. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

  • Francois E. Nader M.D., Independent Chairman of the Board
  • Habib J. Dable, President, Chief Executive Officer, Director
  • Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer
  • Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer
  • Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer
  • John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary
  • Jean M. George, Independent Director
  • George S. Golumbeski Ph.D., Independent Director
  • Terrence C. Kearney, Independent Director
  • Tom Maniatis Ph.D., Independent Director

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of Acceleron Pharma stock can currently be purchased for approximately $38.01.

MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  260 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $43.67 (14.88% upside)
Consensus Price Target History for Acceleron Pharma (NASDAQ:XLRN)
Price Target History for Acceleron Pharma (NASDAQ:XLRN)
Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017HC WainwrightInitiated CoverageBuy -> Buy$57.00N/AView Rating Details
9/20/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
9/20/2017Barclays PLCBoost Price TargetOverweight$42.00 -> $50.00HighView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$44.00LowView Rating Details
9/5/2017CannReiterated RatingHoldLowView Rating Details
8/5/2017Credit Suisse GroupSet Price TargetBuy$35.00LowView Rating Details
8/4/2017Citigroup Inc.Boost Price TargetBuy$44.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$40.00MediumView Rating Details
6/14/2017InstinetReiterated RatingBuy$58.00LowView Rating Details
6/13/2017FBR & CoSet Price TargetBuy$63.00HighView Rating Details
6/13/2017Morgan StanleyLower Price TargetOverweight$51.00 -> $42.00HighView Rating Details
6/13/2017CIBCDowngradeOutperform -> Market PerformLowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Initiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
3/14/2017J P Morgan Chase & CoInitiated CoverageNeutral -> Neutral$33.00HighView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Acceleron Pharma (NASDAQ:XLRN)
Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Earnings History by Quarter for Acceleron Pharma (NASDAQ XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.63)N/AView Earnings Details
8/3/2017Q2 2017($0.65)($0.77)$3.69 million$3.10 millionViewListenView Earnings Details
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
2017 EPS Consensus Estimate: ($2.50)
2018 EPS Consensus Estimate: ($2.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.62)($0.51)($0.57)
Q2 20173($0.69)($0.62)($0.66)
Q3 20173($0.71)($0.59)($0.64)
Q4 20173($0.75)($0.53)($0.63)
Q1 20181($0.56)($0.56)($0.56)
Q2 20181($0.57)($0.57)($0.57)
Q3 20181($0.56)($0.56)($0.56)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)


Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acceleron Pharma (NASDAQ:XLRN)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 77.35%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2017Corp /De/ CelgeneMajor ShareholderBuy745,592$37.00$27,586,904.00View SEC Filing  
9/13/2017John D QuiselSVPSell5,113$38.42$196,441.46View SEC Filing  
9/12/2017Christopher RovaldiSVPSell14,000$38.41$537,740.00View SEC Filing  
9/12/2017Kevin F MclaughlinCFOSell16,000$38.41$614,560.00View SEC Filing  
9/12/2017Matthew L ShermanEVPSell18,400$38.41$706,744.00View SEC Filing  
8/8/2017Ravindra KumarSVPSell13,065$35.41$462,631.65View SEC Filing  
7/5/2017Kevin F MclaughlinCFOSell34,400$32.00$1,100,800.00View SEC Filing  
7/5/2017Matthew L ShermanEVPSell16,000$32.00$512,000.00View SEC Filing  
7/5/2017Ravindra KumarSVPSell937$32.00$29,984.00View SEC Filing  
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.00View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.00View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.00View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.88View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acceleron Pharma (NASDAQ:XLRN)
Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
DateHeadline logoAcceleron Pharma Inc. (XLRN) Coverage Initiated at HC Wainwright - October 15 at 7:56 AM logoAcceleron Pharma Inc. (XLRN) Given Average Recommendation of "Buy" by Analysts - October 12 at 3:16 PM logoOppenheimer Holdings Weighs in on Acceleron Pharma Inc.'s Q3 2017 Earnings (XLRN) - October 9 at 1:02 AM logoAcceleron Pharma Inc. (XLRN) Downgraded to Sell at ValuEngine - October 7 at 9:58 PM logoAcceleron Announces Closing Of Underwriters' Option To Purchase Additional Shares - October 6 at 4:43 AM logo$3.35 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter - October 6 at 2:32 AM logoAcceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares - October 5 at 1:37 PM logoInsider Buying: Acceleron Pharma Inc. (XLRN) Major Shareholder Buys 745,592 Shares of Stock - September 25 at 7:14 PM logoAnalysts Set Expectations for Acceleron Pharma Inc.'s Q3 2017 Earnings (XLRN) - September 25 at 1:16 AM logoAcceleron Pharma Inc. (XLRN) PT Raised to $50.00 at Barclays PLC - September 23 at 9:02 PM logoAcceleron Announces Pricing of Public Offering of Common Stock - September 23 at 12:32 PM logoWhat Is Acceleron Pharma Inc’s (XLRN) Share Price Doing? - September 23 at 12:32 PM logoOppenheimer Holdings, Inc. Reiterates "Hold" Rating for Acceleron Pharma Inc. (XLRN) - September 20 at 3:52 PM logoAcceleron Pharma (XLRN) Plans $150M Offering of Common Stock - September 20 at 11:20 AM logoAcceleron to Develop Sotatercept in Pulmonary Arterial Hypertension - September 19 at 9:52 AM logoAcceleron Pharma Inc. (XLRN) Given Consensus Recommendation of "Buy" by Analysts - September 17 at 10:36 AM logoAcceleron Pharma Inc. (XLRN) SVP Sells $196,441.46 in Stock - September 14 at 11:36 PM logoRoyal Bank Of Canada Begins Coverage on Acceleron Pharma Inc. (XLRN) - September 14 at 11:06 PM logoAcceleron Pharma Inc. (XLRN) EVP Sells $706,744.00 in Stock - September 14 at 10:52 PM logoAcceleron Pharma Inc. (XLRN) CFO Kevin F. Mclaughlin Sells 16,000 Shares - September 14 at 10:52 PM logoChristopher Rovaldi Sells 14,000 Shares of Acceleron Pharma Inc. (XLRN) Stock - September 14 at 10:52 PM logoAcceleron to Host Research and Development Day on September 19, 2017 - September 12 at 12:27 PM logoUBS AG Reiterates "Buy" Rating for Acceleron Pharma Inc. (XLRN) - September 12 at 9:32 AM logoETFs with exposure to Acceleron Pharma, Inc. : September 7, 2017 - September 8 at 10:42 AM logoAcceleron Pharma Inc. to Post Q1 2018 Earnings of ($0.68) Per Share, Oppenheimer Holdings Forecasts (XLRN) - September 7 at 10:26 AM logoAcceleron Pharma Inc. (XLRN) Receives "Hold" Rating from Cann - September 6 at 12:52 AM logoAcceleron Pharma (XLRN) Reports Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results - September 5 at 3:26 PM logoAcceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology - September 5 at 3:26 PM logoAcceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 - September 5 at 3:26 PM logoOppenheimer Holdings, Inc. Reaffirms Hold Rating for Acceleron Pharma Inc. (XLRN) - September 5 at 2:16 PM logoStocks To Watch: Acceleron Pharma Sees Relative Strength Rating Jump To 93 - August 30 at 11:22 AM logoAcceleron Pharma Inc. (XLRN) Receives Average Rating of "Buy" from Analysts - August 23 at 12:44 PM logo Brokerages Expect Acceleron Pharma Inc. (NASDAQ:XLRN) Will Post Quarterly Sales of $3.45 Million - August 12 at 10:16 AM logoLuspatercept: Opportunity for Celgene’s Long-Term Growth? - August 11 at 9:12 AM logoRavindra Kumar Sells 13,065 Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) Stock - August 9 at 8:22 PM logoAcceleron Pharma Inc. (XLRN) Price Target Raised to $44.00 at Citigroup Inc. - August 7 at 12:20 AM logoCredit Suisse Group Analysts Give Acceleron Pharma Inc. (XLRN) a $35.00 Price Target - August 6 at 8:56 AM logoAcceleron Pharma Reports Second Quarter 2017 Operational and Financial Results - August 4 at 10:13 AM logoEdited Transcript of XLRN earnings conference call or presentation 3-Aug-17 9:00pm GMT - August 4 at 10:13 AM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Announces Quarterly Earnings Results - August 3 at 7:26 PM logoAcceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease - August 1 at 7:59 AM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Receives Average Rating of "Buy" from Analysts - July 29 at 10:39 AM logoAcceleron Pharma's (NASDAQ:XLRN) "Buy" Rating Reiterated at Piper Jaffray Companies - July 28 at 7:53 AM logoAcceleron to Webcast Second Quarter 2017 Financial Results on August 3, 2017 - July 27 at 9:46 AM logoAcceleron Pharma Inc. (XLRN) Set to Announce Earnings on Wednesday - July 26 at 7:10 AM logoAcceleron Pharma Inc. (NASDAQ:XLRN) SVP Sells $29,984.00 in Stock - July 7 at 9:02 PM logoAcceleron Pharma Inc. (XLRN) EVP Sells $512,000.00 in Stock - July 7 at 8:16 PM logoAcceleron Pharma Inc. (XLRN) CFO Sells $1,100,800.00 in Stock - July 7 at 7:57 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Receives Consensus Recommendation of "Buy" from Brokerages - July 4 at 11:06 AM logoAcceleron Pharma (XLRN) Presents Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia - June 23 at 8:21 PM



Acceleron Pharma (XLRN) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.